AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18186976 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-sulfamethoxypyrazine-pyrimethamine (AS-SMP) administered with a 12-h or 24-h interval between tablets.
Number of subjects: 14
Study 18186976 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AT-LU) given over 3 days.
Number of subjects: 14
Study 16338010 — intervention group
Group type: EXPERIMENTAL
Intervention: OxLDL levels >76 U/L
Number of subjects: 433
Study 16338010 — intervention group
Group type: EXPERIMENTAL
Intervention: OxLDL levels >76 U/L in TnT negative group
Number of subjects: 433
Study 16338010 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 433
Study 16338010 — intervention group
Group type: COMPARATOR
Intervention: OxLDL levels ≤76 U/L
Number of subjects: 433
Study 16338010 — intervention group
Group type: EXPERIMENTAL
Intervention: OxLDL levels
Number of subjects: 433
Study 14564381 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital care
Number of subjects: 165
Study 14564381 — intervention group
Group type: COMPARATOR
Intervention: Home treatment
Number of subjects: 165
Study 10851665 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) therapy
Number of subjects: 30
Study 10851665 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) therapy
Number of subjects: 30
Study 10851665 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 30
Study 8616946 — intervention group
Group type: EXPERIMENTAL
Intervention: Orgaran (750 anti-Factor Xa units subcutaneously every 12 hours for 14 days)
Number of subjects: 251
Study 8616946 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg orally twice daily for 14 days)
Number of subjects: 251
Study 8616946 — intervention group
Group type: EXPERIMENTAL
Intervention: Orgaran
Number of subjects: 251
Study 8616946 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 251
Study 1917227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone-decanoate (100 mg weekly i.m. injection)
Number of subjects: 5
Study 1917227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 7050440 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) program consisting of stepped-care treatment for hypertension, counseling for cigarette smoking, and dietary advice for lowering blood cholesterol levels
Number of subjects: 12866
Study 7050440 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 12866
Study 7050440 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) program
Number of subjects: 12866
Study 3873785 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 100
Study 3873785 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 100
Study 3873785 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery (subgroup analysis)
Number of subjects: 100
Study 3873785 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery (beta blockers)
Number of subjects: 100
Study 31363948 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive outreach intervention
Number of subjects: 939
Study 31363948 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 939
Study 29471132 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval body weight training (HIBWT)
Number of subjects: 16
Study 29471132 — intervention group
Group type: COMPARATOR
Intervention: Combined training (COMT)
Number of subjects: 16
Study 27516093 — intervention group
Group type: EXPERIMENTAL
Intervention: Utidelone (25 to 35 mg/m2/day intravenously infused once daily for 5 days) in combination with capecitabine (2000 mg/m2 divided in two equal daily oral doses for 14 days)
Number of subjects: 96
Study 27516093 — intervention group
Group type: EXPERIMENTAL
Intervention: Utidelone (40 mg/m2/day intravenously infused once daily for 5 days) as monotherapy
Number of subjects: 96
Study 25056208 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health outreach with culturally tailored educational materials (Group 1)
Number of subjects: 600
Study 25056208 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized comprehensive cervical cancer CHW-led education session followed by patient navigation (Group 2)
Number of subjects: 600
Study 25056208 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation to a Pap smear test or performing HPV self-sampling (Group 3)
Number of subjects: 600
Study 22810619 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE analgesia
Number of subjects: 1140
Study 22810619 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 1140
Study 22810619 — intervention group
Group type: COMPARATOR
Intervention: PCIA with remifentanil
Number of subjects: 1140
Study 20361306 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 20
Study 20361306 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 20
Study 18460588 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 125
Study 18460588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 18460588 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 125
Study 16001377 — intervention group
Group type: EXPERIMENTAL
Intervention: 1CU Human Optics intraocular lens
Number of subjects: 20
Study 16001377 — intervention group
Group type: COMPARATOR
Intervention: AcrySof intraocular lens
Number of subjects: 20
Study 12461831 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 58
Study 12461831 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 58
Study 10624752 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue electrical stimulation (TES)
Number of subjects: 7
Study 7733193 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoviral conjunctivitis
Number of subjects: 100
Study 2109470 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (36 micrograms.kg‐1)
Number of subjects: 12
Study 2109470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6270998 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber diet (59 g neutral detergent fiber)
Number of subjects: 8
Study 6270998 — intervention group
Group type: COMPARATOR
Intervention: Control diet (21 g neutral detergent fiber)
Number of subjects: 8
Study 6270998 — intervention group
Group type: COMPARATOR
Intervention: Low fiber diet (21 g neutral detergent fiber)
Number of subjects: 8
Study 30394995 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette and marijuana co-use
Number of subjects: 500
Study 29432640 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond burs
Number of subjects: 12
Study 29432640 — intervention group
Group type: COMPARATOR
Intervention: Curettes
Number of subjects: 12
Study 25683164 — intervention group
Group type: EXPERIMENTAL
Intervention: Familias Unidas intervention
Number of subjects: 242
Study 25683164 — intervention group
Group type: COMPARATOR
Intervention: Community practice control
Number of subjects: 242
Study 25467093 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (Group A)
Number of subjects: 80
Study 25467093 — intervention group
Group type: COMPARATOR
Intervention: Control (Group B)
Number of subjects: 80
Study 22184645 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified version of the Mother‐Infant Transaction Program
Number of subjects: 146
Study 22184645 — intervention group
Group type: COMPARATOR
Intervention: Preterm control group
Number of subjects: 146
Study 22184645 — intervention group
Group type: COMPARATOR
Intervention: Term reference group
Number of subjects: 146
Study 20209375 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg)
Number of subjects: 12
Study 20209375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18160763 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blocker (ARB) - 50 mg of losartan potassium administered once daily for one year
Number of subjects: 19
Study 18160763 — intervention group
Group type: COMPARATOR
Intervention: Non-ARB group (control)
Number of subjects: 19
Study 15886228 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (6 mg)
Number of subjects: 27
Study 10785238 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU/d recombinant FSH starting on cycle day 5 with 0.25 mg/d GnRH antagonist from cycle day 8
Number of subjects: 15
Study 10785238 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU/d recombinant FSH starting on cycle day 5 with 0.25 mg/d GnRH antagonist from cycle day 8
Number of subjects: 15
Study 10785238 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU/d recombinant FSH starting in the midfollicular phase
Number of subjects: 15
Study 10785238 — intervention group
Group type: EXPERIMENTAL
Intervention: No luteal support provided
Number of subjects: 15
Study 9301500 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg once daily
Number of subjects: 178
Study 9301500 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 4.5 mg twice daily
Number of subjects: 178
Study 9301500 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 40 mg once daily
Number of subjects: 178
Study 8280824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg q.d.s., 7 days)
Number of subjects: 12
Study 8280824 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid Gaviscon (sodium alginate compound)
Number of subjects: 12
Study 8280824 — intervention group
Group type: COMPARATOR
Intervention: Control period (no cimetidine)
Number of subjects: 12
Study 3552444 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoprecipitate infusion
Number of subjects: 32
Study 3552444 — intervention group
Group type: COMPARATOR
Intervention: Control infusion
Number of subjects: 32
Study 31680010 — intervention group
Group type: EXPERIMENTAL
Intervention: BioFoam® Surgical Matrix
Number of subjects: 101
Study 31680010 — intervention group
Group type: COMPARATOR
Intervention: Control (without use of BioFoam®)
Number of subjects: 101
Study 30246557 — intervention group
Group type: EXPERIMENTAL
Intervention: HiBalance training program (10-week, three times per week, group-based, led by two physical therapists)
Number of subjects: 100
Study 30246557 — intervention group
Group type: EXPERIMENTAL
Intervention: HiBalance training program
Number of subjects: 100
Study 30246557 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 100
Study 28368158 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 48
Study 28368158 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 48
Study 25765696 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 5380
Study 25765696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5380
Study 23449130 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of a mixture of Trifolium pratense flower extract and a biomimetic peptide
Number of subjects: 30
Study 23449130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21593619 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly peginterferon-α-2a 180 μg/week (for 4 weeks, followed by weekly dosing) and weight-based ribavirin (1-1.2 g/day)
Number of subjects: 0
Study 21593619 — intervention group
Group type: COMPARATOR
Intervention: Weekly peginterferon-α-2a 180 μg/week and weight-based ribavirin (1-1.2 g/day)
Number of subjects: 0
Study 19619692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous unfractionated heparin (UFH) bolus 70 IU/kg
Number of subjects: 72
Study 19619692 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous enoxaparin (1 mg/kg every 12 hours for 2.5 days)
Number of subjects: 72
Study 16960935 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 39141 (625 microg)
Number of subjects: 36
Study 16960935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 14758100 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: 70% of heart rate reserve using precise, continuous electronic heart rate‐controlled resistance on a cycle ergometer
Number of subjects: 78
Study 14758100 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Self-regulated exercise intensity at 'somewhat hard' (13 on the Borg scale) with no feedback
Number of subjects: 78
Study 14758100 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: Exercise intensity determined using objective (heart rate reserve and work rate targeted to 60% to 80% of maximal exercise) and subjective (Borg scale 12 to 14) indices
Number of subjects: 78
Study 11044536 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E(2) intravaginal gel (2 mg)
Number of subjects: 470
Study 11044536 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E(2) intracervical gel (0.5 mg)
Number of subjects: 470
Study 9340633 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoset-CPAP
Number of subjects: 12
Study 9340633 — intervention group
Group type: COMPARATOR
Intervention: Constant CPAP
Number of subjects: 12
Study 8141719 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 800
Study 8141719 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 800
Study 8141719 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 800
Study 3525584 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training (SST)
Number of subjects: 50
Study 3525584 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo control (APC)
Number of subjects: 50
Study 3525584 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control (NTC)
Number of subjects: 50
Study 29124498 — intervention group
Group type: EXPERIMENTAL
Intervention: RT1 (Resistance Training 1, n=26)
Number of subjects: 106
Study 29124498 — intervention group
Group type: EXPERIMENTAL
Intervention: RT2 (Resistance Training 2, n=27)
Number of subjects: 106
Study 29124498 — intervention group
Group type: EXPERIMENTAL
Intervention: RT3 (Resistance Training 3, n=28)
Number of subjects: 106
Study 29124498 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=25)
Number of subjects: 106
Study 27914492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy (90 mg twice daily) plus low-dose aspirin (81-100 mg daily) for 3 months, then ticagrelor plus placebo for 12 months
Number of subjects: 9000
Study 27914492 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor plus low-dose aspirin (81-100 mg daily) for 3 months, then continuation of ticagrelor plus aspirin
Number of subjects: 9000
Study 25618415 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMOXEL (GEM 1,000 mg/m², L-OHP 100 mg/m², CAP 1,500 mg/m²/day)
Number of subjects: 67
Study 25618415 — intervention group
Group type: COMPARATOR
Intervention: GEM (GEM 1,000 mg/m²)
Number of subjects: 67
Study 24524600 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation clinic follow‐up group (n = 70)
Number of subjects: 140
Study 24524600 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group (n = 70)
Number of subjects: 140
Study 21943132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive periodontal therapy involving removal of subgingival and supragingival calculus and plaque biofilm by scaling and root‐planing.
Number of subjects: 0
Study 21943132 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention for 12 months).
Number of subjects: 0
Study 18301974 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus resistance training (DR)
Number of subjects: 42
Study 18301974 — intervention group
Group type: COMPARATOR
Intervention: Diet only (D)
Number of subjects: 42
Study 16530290 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha treatment in CHB patients
Number of subjects: 105
Study 16530290 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha treatment in CHC patients
Number of subjects: 105
Study 16530290 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 105
Study 16530290 — intervention group
Group type: COMPARATOR
Intervention: Diseased controls (autoimmune liver diseases)
Number of subjects: 105
Study 14580749 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (SB)
Number of subjects: 87
Study 14580749 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrins
Number of subjects: 87
Study 10613766 — intervention group
Group type: EXPERIMENTAL
Intervention: Purple grape juice (5-7.5 mL/(kg. d) for 7-10 days)
Number of subjects: 10
Study 10613766 — intervention group
Group type: COMPARATOR
Intervention: Orange juice (5-7.5 mL/(kg. d) for 7-10 days)
Number of subjects: 10
Study 10613766 — intervention group
Group type: COMPARATOR
Intervention: Grapefruit juice (5-7.5 mL/(kg. d) for 7-10 days)
Number of subjects: 10
Study 7981069 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron plus dexamethasone
Number of subjects: 278
Study 7981069 — intervention group
Group type: COMPARATOR
Intervention: Granisetron alone
Number of subjects: 278
Study 2923769 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.25% bupivacaine through an extradural catheter
Number of subjects: 20
Study 2923769 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.25% bupivacaine through a paravertebral catheter
Number of subjects: 20
Study 30855076 — intervention group
Group type: EXPERIMENTAL
Intervention: GP endorsement via letter
Number of subjects: 110
Study 30855076 — intervention group
Group type: EXPERIMENTAL
Intervention: GP endorsement via SMS
Number of subjects: 110
Study 30855076 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust in GP
Number of subjects: 110
Study 30855076 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative endorsers suggested
Number of subjects: 110
Study 29079990 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (2 × 10^9 CFU/g each of Lactobacillus acidophilus strain T16, Lactobacillus casei strain T2, and Bifidobacterium bifidum strain T1 plus 800 mg inulin)
Number of subjects: 60
Study 29079990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29103871 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (100 mg twice daily) plus paclitaxel (80 mg/m2 intravenously)
Number of subjects: 525
Study 29103871 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel (80 mg/m2 intravenously)
Number of subjects: 525
Study 26412226 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning and coping education strategies (LC)
Number of subjects: 825
Study 26412226 — intervention group
Group type: COMPARATOR
Intervention: Standard education (standard)
Number of subjects: 825
Study 23627538 — intervention group
Group type: EXPERIMENTAL
Intervention: Harris coloured filters
Number of subjects: 73
Study 23627538 — intervention group
Group type: EXPERIMENTAL
Intervention: DRT coloured filters
Number of subjects: 73
Study 21797811 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 11
Study 21797811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 19028042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryo stripping
Number of subjects: 494
Study 19028042 — intervention group
Group type: COMPARATOR
Intervention: Conventional stripping
Number of subjects: 494
Study 17541058 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 42
Study 17541058 — intervention group
Group type: COMPARATOR
Intervention: Cortisone (25 mg)
Number of subjects: 42
Study 17541058 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisone (25 mg) + Propranolol (40 mg)
Number of subjects: 42
Study 17541058 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol alone
Number of subjects: 42
Study 15340092 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulphone membrane during haemodialysis
Number of subjects: 24
Study 15340092 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyamide membrane during haemodialysis
Number of subjects: 24
Study 15340092 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulphone membrane perfused with blood without dialysate
Number of subjects: 24
Study 15340092 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyamide membrane perfused with blood without dialysate
Number of subjects: 24
Study 11489714 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraurethral prostaglandin E(1) (MUSE)
Number of subjects: 72
Study 9880199 — intervention group
Group type: EXPERIMENTAL
Intervention: ST elevation
Number of subjects: 0
Study 9880199 — intervention group
Group type: EXPERIMENTAL
Intervention: ST depression
Number of subjects: 0
Study 9880199 — intervention group
Group type: COMPARATOR
Intervention: No ST changes
Number of subjects: 0
Study 9880199 — intervention group
Group type: EXPERIMENTAL
Intervention: ST segment depression
Number of subjects: 0
Study 9880199 — intervention group
Group type: EXPERIMENTAL
Intervention: ST segment elevation
Number of subjects: 0
Study 9880199 — intervention group
Group type: COMPARATOR
Intervention: No ST deviation
Number of subjects: 0
Study 9880199 — intervention group
Group type: EXPERIMENTAL
Intervention: ST segment depression vs ST elevation
Number of subjects: 0
Study 9880199 — intervention group
Group type: EXPERIMENTAL
Intervention: ST elevation with concomitant ST depression
Number of subjects: 0
Study 9880199 — intervention group
Group type: COMPARATOR
Intervention: ST elevation without concomitant ST depression
Number of subjects: 0
Study 7572617 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (85% of maximal oxygen consumption)
Number of subjects: 200
Study 7572617 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity exercise training (50% of maximal oxygen consumption)
Number of subjects: 200
Study 2205962 — intervention group
Group type: EXPERIMENTAL
Intervention: Early occupational therapy (1-3 days after injury)
Number of subjects: 40
Study 2205962 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 40
Study 6107722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of acetylsalicylic acid
Number of subjects: 0
Study 6107722 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone acetate
Number of subjects: 0
Study 6107722 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0